The treatment landscape for irritable bowel syndrome with constipation (IBS-C) is undergoing rapid transformation as healthcare providers increasingly focus on patient-centric gastrointestinal care solutions. Growing awareness regarding chronic digestive disorders, coupled with the rising prevalence of gastrointestinal complications worldwide, is encouraging pharmaceutical companies to invest...